Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of SAB-301 in healthy adults; the study completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle East Respiratory Syndrome

Drugs mentioned

• SAB-301

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Middle East Respiratory Syndrome Coronavirus | Phase 1 | Status: COMPLETED | Results posted: 2018-06-12